Advancing CAR-T therapy in prostate cancer: overcoming the tumor microenvironment and enhancing efficacy - PubMed
a day ago
- #tumor microenvironment
- #CAR-T therapy
- #prostate cancer
- Prostate cancer (PCa) is a common malignancy in men, with limited treatment options for metastatic castration-resistant PCa (mCRPC).
- CAR-T therapy has shown success in hematologic cancers but faces challenges in PCa due to scarce tumor-specific antigens, immunosuppressive tumor microenvironment (TME), antigen heterogeneity, and safety concerns.
- Emerging strategies include next-generation CAR designs like cytokine-armed CAR-T cells, gene editing (e.g., PD-1 disruption), and metabolic reprogramming to enhance efficacy.
- Combination approaches with other therapies and multi-antigen CARs are being explored to overcome antigen escape and T cell exhaustion.
- Early clinical trials in PCa show CAR-T cells can recognize prostate-associated antigens and elicit immune responses, though durable remissions are rare.
- The review highlights ongoing innovations in CAR design and therapeutic combinations to improve CAR-T therapy for advanced prostate cancer.